John Joseph Reynolds-Wright
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John Joseph Reynolds-Wright has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Sharon Cameron
Sexual and Reproductive Health, NHS Lothian, Edinburgh, UK
21 shared publications - Jeni Harden
Centre for Biomedicine Self and Society, Usher Institute, The University of Edinburgh
5 shared publications - Nicola Boydell
Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK
5 shared publications Karen McCabe
Centre for Reproductive Health, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK
4 shared publications- Jacqueline Quinn
Centre for Reproductive Health, Institute for Repair and Regeneration, The University of Edinburgh, Edinburgh, UK
3 shared publications Sharon Cameron
3 shared publications
Latest Publications
- 16 November 2026
- Published by BMJ in BMJ Sexual & Reproductive Health
Home use of mifepristone before mid-trimester abortion: a retrospective cohort study
- 16 November 2026
- Published by BMJ in BMJ Sexual & Reproductive Health
Home use of mifepristone before mid-trimester abortion: a retrospective cohort study
- Open Access
- 29 April 2026
- Published by Taylor & Francis in Future Science OA
- Vol. 12 (1) , 2664612
Novel male contraceptives
1. Unintended pregnancies are common, with data demonstrating that 121 million unintended pregnancies occur globally each year [1]. A wide range of contraceptive options is essential to allow indiv...
- 29 April 2026
- Published by Taylor & Francis in Future Science OA
- Vol. 12 (1) , 2664612
Open AccessNovel male contraceptives
1. Unintended pregnancies are common, with data demonstrating that 121 million unintended pregnancies occur globally each year [1]. A wide range of contraceptive options is essential to allow indiv...
- 30 March 2026
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (3) , 227-229
Abortion exceptionalism in research governance: why naming the problem matters
As an interdisciplinary group of researchers of abortion, contraception and sexual and reproductive health, we have observed a subtle but significant intensification of abortion exceptionalism in recent years. In this Personal View, we argue that this exceptionalism is being reproduced through research governance processes, including ethics review and expectations around public and patient involvement and engagement. These shifts have implications not only for service provision, but for what kinds of abortion research are considered fundable, feasible and ethical.
- 30 March 2026
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (3) , 227-229
Abortion exceptionalism in research governance: why naming the problem matters
As an interdisciplinary group of researchers of abortion, contraception and sexual and reproductive health, we have observed a subtle but significant intensification of abortion exceptionalism in recent years. In this Personal View, we argue that this exceptionalism is being reproduced through research governance processes, including ethics review and expectations around public and patient involvement and engagement. These shifts have implications not only for service provision, but for what kinds of abortion research are considered fundable, feasible and ethical.
- 16 January 2026
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (3) , 230-233
Implementing a point-of-care test for β-human chorionic gonadotropin testing within an abortion service
- 16 January 2026
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (3) , 230-233
Implementing a point-of-care test for β-human chorionic gonadotropin testing within an abortion service
- Open Access
- 1 January 2026
- Published by Bioscientifica in Reproduction and Fertility
- Vol. 7 (1)
Advantages and disadvantages of peri-abortion ultrasonography
Ultrasonography remains an important component of abortion care, as it does in early pregnancy in general. We propose that selective use of ultrasonography, in line with World Health Organization recommendations, allows clinicians and services to maximise the advantages of peri-abortion ultrasound while minimising the impact of the disadvantages of the technology. Patient preferences should be prioritised where possible and safe to do so. Lay summary: Ultrasound scanning before, during, or after an abortion can be helpful to guide patient care. However, using this for all patients in all scenarios can lead to problems with inappropriate diagnosis or over-diagnosis of conditions and complications. We recommend that ultrasound scanning be used only when needed and guided by evidence-based guidelines and protocols, in line with the World Health Organization.
- 1 January 2026
- Published by Bioscientifica in Reproduction and Fertility
- Vol. 7 (1)
Open AccessAdvantages and disadvantages of peri-abortion ultrasonography
Ultrasonography remains an important component of abortion care, as it does in early pregnancy in general. We propose that selective use of ultrasonography, in line with World Health Organization recommendations, allows clinicians and services to maximise the advantages of peri-abortion ultrasound while minimising the impact of the disadvantages of the technology. Patient preferences should be prioritised where possible and safe to do so. Lay summary: Ultrasound scanning before, during, or after an abortion can be helpful to guide patient care. However, using this for all patients in all scenarios can lead to problems with inappropriate diagnosis or over-diagnosis of conditions and complications. We recommend that ultrasound scanning be used only when needed and guided by evidence-based guidelines and protocols, in line with the World Health Organization.
- 27 November 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 133 (4) , 647-648
Improving Access to Medical Abortion Services: Results From Ghana and Cambodia
Linked article: This is a mini commentary on Kapp et al., pp. 553–561 in this issue. To view this article visit https://doi.org/10.1111/1471‐0528.18344 .
- 27 November 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 133 (4) , 647-648
Improving Access to Medical Abortion Services: Results From Ghana and Cambodia
Linked article: This is a mini commentary on Kapp et al., pp. 553–561 in this issue. To view this article visit https://doi.org/10.1111/1471‐0528.18344 .
- Open Access
- 2 October 2025
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (1) , 57-62
Safety and efficacy of early medical abortion at home between 10+0 and 11+6 weeks' gestation: a retrospective review
Introduction: Since 2020, legislation in Britain has allowed both mifepristone and misoprostol to be taken at home for early medical abortion (EMA). In England and Wales, legislation restricts this to 9+6 weeks, but in Scotland this is permitted up to 11+6 weeks. Data on the outcomes of EMA at home >10 weeks’ gestation is limited and so we aimed to establish the safety and efficacy of this in comparison with EMA in a hospital setting. Methods: We conducted a retrospective review from our abortion service in Edinburgh, Scotland of outcomes of EMA at home versus hospital between 10+0 and 11+6 weeks' gestation over the 5-year period April 2020–March 2025. The primary outcome was complete abortion rate. Secondary outcomes were rates of incomplete abortion, ongoing pregnancy and serious complications. Results: A total of 371 EMAs occurred at this gestation (n=258 home, n=113 hospital). Complete abortion rates were not statistically significantly different between groups: 251/258 (97%) (95% CI: 94% to 99%) at home and 110/113 (97%) (95% CI: 92% to 99%) in hospital. Neither incomplete abortion rates (home: 4/258, 1.6%; hospital: 3/113, 2.6%) nor ongoing pregnancy rates (home: 3/258, 1.2%; hospital: 0/113, 0%) were significantly different between groups. There was one case of haemorrhage requiring transfusion and three cases of infection receiving intravenous antibiotics, all in the at home group. Conclusions: EMA at home between 10+0 and 11+6 weeks has the same high efficacy and safety as when conducted in hospital. Action is needed to extend EMA at home after 10 weeks' gestation to women across the rest of the UK and beyond.
- 2 October 2025
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (1) , 57-62
Open AccessSafety and efficacy of early medical abortion at home between 10+0 and 11+6 weeks' gestation: a retrospective review
Introduction: Since 2020, legislation in Britain has allowed both mifepristone and misoprostol to be taken at home for early medical abortion (EMA). In England and Wales, legislation restricts this to 9+6 weeks, but in Scotland this is permitted up to 11+6 weeks. Data on the outcomes of EMA at home >10 weeks’ gestation is limited and so we aimed to establish the safety and efficacy of this in comparison with EMA in a hospital setting. Methods: We conducted a retrospective review from our abortion service in Edinburgh, Scotland of outcomes of EMA at home versus hospital between 10+0 and 11+6 weeks' gestation over the 5-year period April 2020–March 2025. The primary outcome was complete abortion rate. Secondary outcomes were rates of incomplete abortion, ongoing pregnancy and serious complications. Results: A total of 371 EMAs occurred at this gestation (n=258 home, n=113 hospital). Complete abortion rates were not statistically significantly different between groups: 251/258 (97%) (95% CI: 94% to 99%) at home and 110/113 (97%) (95% CI: 92% to 99%) in hospital. Neither incomplete abortion rates (home: 4/258, 1.6%; hospital: 3/113, 2.6%) nor ongoing pregnancy rates (home: 3/258, 1.2%; hospital: 0/113, 0%) were significantly different between groups. There was one case of haemorrhage requiring transfusion and three cases of infection receiving intravenous antibiotics, all in the at home group. Conclusions: EMA at home between 10+0 and 11+6 weeks has the same high efficacy and safety as when conducted in hospital. Action is needed to extend EMA at home after 10 weeks' gestation to women across the rest of the UK and beyond.
- 27 August 2025
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (2) , 120-129
‘Problem representations’ in post-abortion contraception: a critical review of UK literature
Objective: To critically review post-abortion contraception literature from the UK based on Bacchi’s ‘What’s the Problem Represented to Be?’ (WPR) approach. Methods: A systematic search of six electronic databases – complemented by a grey literature search encompassing reports, policy documents and government publications – identified a total of 31 publications: 19 peer-reviewed articles and 12 items of grey literature. Results: Multiple – and sometimes conflicting – ‘problem representations’ coexisted across the texts, operating at different levels of abstraction. Applying the WPR approach, six ‘problems’ were identified: existing abortion rates and repeat abortion; risky groups; meeting service users’ needs; organisational capacity; knowledge of contraceptive methods; and abortion stigma. Conclusions: While some problem representations focused on service user needs, care satisfaction and organisational capacity, the dominant framing positioned abortion rates – particularly subsequent abortions – as the central ‘problem’. It is implied that too many abortions are being had and that a key purpose of post-abortion contraception is to address this issue. Abortion was often framed as an individual’s failure to use (effective) contraception (correctly). This places the burden on individuals, further exacerbates abortion stigma and obscures structural constraints. Several conceptual slippages were identified, including using ‘unplanned’, ‘unintended’ and ‘unwanted’ pregnancy synonymously. Such practices risk collapsing and misrepresenting different kinds of lived experiences, creating barriers to the provision of person-centred abortion and contraceptive care. We recommend greater critical reflection on the language and assumptions within post-abortion contraception discourse to ensure research, policy and practice remain person-centred, evidence-informed and committed to principles of reproductive justice.
- 27 August 2025
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (2) , 120-129
‘Problem representations’ in post-abortion contraception: a critical review of UK literature
Objective: To critically review post-abortion contraception literature from the UK based on Bacchi’s ‘What’s the Problem Represented to Be?’ (WPR) approach. Methods: A systematic search of six electronic databases – complemented by a grey literature search encompassing reports, policy documents and government publications – identified a total of 31 publications: 19 peer-reviewed articles and 12 items of grey literature. Results: Multiple – and sometimes conflicting – ‘problem representations’ coexisted across the texts, operating at different levels of abstraction. Applying the WPR approach, six ‘problems’ were identified: existing abortion rates and repeat abortion; risky groups; meeting service users’ needs; organisational capacity; knowledge of contraceptive methods; and abortion stigma. Conclusions: While some problem representations focused on service user needs, care satisfaction and organisational capacity, the dominant framing positioned abortion rates – particularly subsequent abortions – as the central ‘problem’. It is implied that too many abortions are being had and that a key purpose of post-abortion contraception is to address this issue. Abortion was often framed as an individual’s failure to use (effective) contraception (correctly). This places the burden on individuals, further exacerbates abortion stigma and obscures structural constraints. Several conceptual slippages were identified, including using ‘unplanned’, ‘unintended’ and ‘unwanted’ pregnancy synonymously. Such practices risk collapsing and misrepresenting different kinds of lived experiences, creating barriers to the provision of person-centred abortion and contraceptive care. We recommend greater critical reflection on the language and assumptions within post-abortion contraception discourse to ensure research, policy and practice remain person-centred, evidence-informed and committed to principles of reproductive justice.
- Open Access
- 20 May 2025
- Published by Taylor & Francis in The European Journal of Contraception & Reproductive Health Care
- Vol. 30 (4) , 216-220
The CPLAN study: Clotting Parameters after medicaL AbortioN
There is paucity of information on coagulation parameters throughout pregnancy, the puerperium, and post-abortion - and how these relate to venous thromboembolism (VTE) risk. Guidance for thromboprophylaxis post-abortion is guided by expert opinion and extrapolated from post-birth, with recommendations varying from 0 to 6 weeks duration. We conducted a study in a community abortion clinic in Edinburgh, UK March-August 2021. We recruited healthy pregnant women requesting medical abortion (p = 0.04), although remained within normal range. Two viscoelastic measures showed pro-coagulant changes, one pre-abortion and one post-abortion compared to controls. The absolute differences were small and remained within normal ranges. There were minimal differences in measures of coagulation in first trimester pregnancy, that largely resolved 10-14 days after medical abortion. Shorter courses of thromboprophylaxis might be sufficient compared to post-birth for those at high risk of VTE.
- 20 May 2025
- Published by Taylor & Francis in The European Journal of Contraception & Reproductive Health Care
- Vol. 30 (4) , 216-220
Open AccessThe CPLAN study: Clotting Parameters after medicaL AbortioN
There is paucity of information on coagulation parameters throughout pregnancy, the puerperium, and post-abortion - and how these relate to venous thromboembolism (VTE) risk. Guidance for thromboprophylaxis post-abortion is guided by expert opinion and extrapolated from post-birth, with recommendations varying from 0 to 6 weeks duration. We conducted a study in a community abortion clinic in Edinburgh, UK March-August 2021. We recruited healthy pregnant women requesting medical abortion (p = 0.04), although remained within normal range. Two viscoelastic measures showed pro-coagulant changes, one pre-abortion and one post-abortion compared to controls. The absolute differences were small and remained within normal ranges. There were minimal differences in measures of coagulation in first trimester pregnancy, that largely resolved 10-14 days after medical abortion. Shorter courses of thromboprophylaxis might be sufficient compared to post-birth for those at high risk of VTE.
- 23 February 2025
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (1) , 32-37
Early medical abortion before missed menses: outcomes of abortion at less than 30 days from last menstrual period
Introduction: High-sensitivity urine pregnancy tests can detect pregnancy before missed menses. The widespread availability of these tests, alongside improvements in abortion access in many settings, may mean more women present for abortion at a very early stage of pregnancy. We aimed to examine the outcome of early medical abortion (EMA) in pregnancies less than 30 days from last menstrual period (LMP). Methods: This study analysed prospectively collected data on patients at less than 30 days from LMP seeking abortion at a single service in Edinburgh, UK between March 2020 and December 2023. We determined the effectiveness, outcomes of the pregnancy (complete abortion, ongoing pregnancy, incomplete abortion) and serious complications among those seeking EMA at this gestation. Results: Of 13 565 patients seeking abortion, 78 (0.6%) presented with a self-reported positive home pregnancy test and less than 30 days from LMP. Some 63/78 patients (81%) proceeded to EMA with mifepristone followed by misoprostol. Of this group, 31/63 (49%) had a pre-abortion ultrasound. Complete abortion occurred in 58/63 (92%, 95% CI 82% to 97%), 4/63 (6%) had an ongoing pregnancy and 1 (1%) had a surgical evacuation for incomplete abortion. There were no serious complications. Conclusions: Only a very small percentage of patients present for abortion before a missed period. Nevertheless, EMA at this stage is safe and effective. There may be a higher rate of ongoing pregnancy, and so those patients wishing to proceed to EMA should be advised of the importance of confirming success in line with local protocols.
- 23 February 2025
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 52 (1) , 32-37
Early medical abortion before missed menses: outcomes of abortion at less than 30 days from last menstrual period
Introduction: High-sensitivity urine pregnancy tests can detect pregnancy before missed menses. The widespread availability of these tests, alongside improvements in abortion access in many settings, may mean more women present for abortion at a very early stage of pregnancy. We aimed to examine the outcome of early medical abortion (EMA) in pregnancies less than 30 days from last menstrual period (LMP). Methods: This study analysed prospectively collected data on patients at less than 30 days from LMP seeking abortion at a single service in Edinburgh, UK between March 2020 and December 2023. We determined the effectiveness, outcomes of the pregnancy (complete abortion, ongoing pregnancy, incomplete abortion) and serious complications among those seeking EMA at this gestation. Results: Of 13 565 patients seeking abortion, 78 (0.6%) presented with a self-reported positive home pregnancy test and less than 30 days from LMP. Some 63/78 patients (81%) proceeded to EMA with mifepristone followed by misoprostol. Of this group, 31/63 (49%) had a pre-abortion ultrasound. Complete abortion occurred in 58/63 (92%, 95% CI 82% to 97%), 4/63 (6%) had an ongoing pregnancy and 1 (1%) had a surgical evacuation for incomplete abortion. There were no serious complications. Conclusions: Only a very small percentage of patients present for abortion before a missed period. Nevertheless, EMA at this stage is safe and effective. There may be a higher rate of ongoing pregnancy, and so those patients wishing to proceed to EMA should be advised of the importance of confirming success in line with local protocols.